用于癌症疫苗的转化型纳米颗粒工程
Translational nanoparticle engineering for cancer vaccines.
作者信息
Grippin Adam J, Sayour Elias J, Mitchell Duane A
机构信息
Preston A. Wells, Jr. Center for Brain Tumor Therapy, University of Florida Brain Tumor Immunotherapy Program, McKnight Brain Institute, Department of Neurosurgery, University of Florida, Gainesville, FL, USA.
J. Crayton Pruitt Family Department of Biomedical Engineering, Biomedical Sciences Building, University of Florida, Gainesville, FL, USA.
出版信息
Oncoimmunology. 2017 Feb 22;6(10):e1290036. doi: 10.1080/2162402X.2017.1290036. eCollection 2017.
Abstract
Conventional cancer treatments remain insufficient to treat many therapy-resistant tumors. Cancer vaccines attempt to overcome this resistance by activating the patient's immune system to eliminate tumor cells without the toxicity of systemic chemotherapy and radiation. Nanoparticles (NPs) are promising as customizable, immunostimulatory carriers to protect and deliver antigen. Although many NP vaccines have been investigated in preclinical settings, a few have advanced into clinical application, and still fewer have demonstrated clinical benefit. This review incorporates observations from NP vaccines that have been evaluated in early phase clinical trials to make recommendations for the next generation of NP-based cancer vaccines.
摘要
传统的癌症治疗方法在治疗许多耐药性肿瘤方面仍然不足。癌症疫苗试图通过激活患者的免疫系统来消除肿瘤细胞，从而克服这种耐药性，同时避免全身化疗和放疗的毒性。纳米颗粒（NPs）作为可定制的免疫刺激载体，有望用于保护和递送抗原。尽管许多纳米颗粒疫苗已在临床前环境中进行了研究，但只有少数进入了临床应用，而且证明有临床益处的更少。本综述纳入了在早期临床试验中评估的纳米颗粒疫苗的观察结果，为下一代基于纳米颗粒的癌症疫苗提出建议。
相似文献
1
Translational nanoparticle engineering for cancer vaccines.用于癌症疫苗的转化型纳米颗粒工程
Oncoimmunology. 2017 Feb 22;6(10):e1290036. doi: 10.1080/2162402X.2017.1290036. eCollection 2017.
2
Engineering Nanoparticles toward the Modulation of Emerging Cancer Immunotherapy.工程纳米颗粒以调节新兴的癌症免疫疗法。
Adv Healthc Mater. 2021 Mar;10(5):e2000845. doi: 10.1002/adhm.202000845. Epub 2020 Aug 12.
3
Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy.癌症的先进靶向疗法：药物纳米载体，化疗的未来。
Eur J Pharm Biopharm. 2015 Jun;93:52-79. doi: 10.1016/j.ejpb.2015.03.018. Epub 2015 Mar 23.
4
Adjuvanting a Simian Immunodeficiency Virus Vaccine with Toll-Like Receptor Ligands Encapsulated in Nanoparticles Induces Persistent Antibody Responses and Enhanced Protection in TRIM5α Restrictive Macaques.用包裹在纳米颗粒中的Toll样受体配体辅助猿猴免疫缺陷病毒疫苗可诱导持续性抗体反应并增强对TRIM5α限制型猕猴的保护。
J Virol. 2017 Jan 31;91(4). doi: 10.1128/JVI.01844-16. Print 2017 Feb 15.
5
6
Enhanced stimulation of anti-breast cancer T cells responses by dendritic cells loaded with poly lactic-co-glycolic acid (PLGA) nanoparticle encapsulated tumor antigens.负载聚乳酸-乙醇酸共聚物（PLGA）纳米颗粒包裹肿瘤抗原的树突状细胞增强抗乳腺癌T细胞反应的刺激作用。
J Exp Clin Cancer Res. 2016 Oct 26;35(1):168. doi: 10.1186/s13046-016-0444-6.
7
Multifunctional nanoparticles for cancer immunotherapy.用于癌症免疫治疗的多功能纳米颗粒。
Hum Vaccin Immunother. 2016 Jul 2;12(7):1863-75. doi: 10.1080/21645515.2016.1147635. Epub 2016 Feb 22.
8
In situ vaccination: Harvesting low hanging fruit on the cancer immunotherapy tree.原位疫苗接种：在癌症免疫治疗树上收获低垂的果实。
Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2019 Jan;11(1):e1524. doi: 10.1002/wnan.1524. Epub 2018 Apr 18.
9
Protein corona-mediated targeting of nanocarriers to B cells allows redirection of allergic immune responses.蛋白冠介导的纳米载体靶向 B 细胞可实现对过敏性免疫应答的重定向。
J Allergy Clin Immunol. 2018 Nov;142(5):1558-1570. doi: 10.1016/j.jaci.2017.08.049. Epub 2018 Jan 31.
10
Nanotechnology as a therapeutic tool to combat microbial resistance.纳米技术作为一种治疗工具，用于对抗微生物耐药性。
Adv Drug Deliv Rev. 2013 Nov;65(13-14):1803-15. doi: 10.1016/j.addr.2013.07.011. Epub 2013 Jul 24.
引用本文的文献
1
Nanotechnology for immuno-oncology.免疫肿瘤学的纳米技术
Nat Cancer. 2025 Aug 7. doi: 10.1038/s43018-025-01025-x.
2
CEA-Functionalized Gold Nanoparticles as a Nanovaccine Platform: In Vitro Evaluation of Cytocompatibility, Cellular Uptake, and Antigen Processing.癌胚抗原功能化金纳米颗粒作为一种纳米疫苗平台：细胞相容性、细胞摄取及抗原加工的体外评估
Vaccines (Basel). 2025 Jun 21;13(7):668. doi: 10.3390/vaccines13070668.
3
Revolutionizing head and neck squamous cell carcinoma treatment with nanomedicine in the era of immunotherapy.在免疫治疗时代，纳米医学为头颈部鳞状细胞癌的治疗带来变革。
Front Immunol. 2024 Nov 29;15:1453753. doi: 10.3389/fimmu.2024.1453753. eCollection 2024.
4
Functionalized PLGA-Based Nanoparticles with Anti-HSV-2 Human Monoclonal Antibody: A Proof of Concept for Early Diagnosis and Targeted Therapy.负载抗单纯疱疹病毒2型人单克隆抗体的功能化聚乳酸-羟基乙酸共聚物纳米颗粒：早期诊断和靶向治疗的概念验证
Pharmaceutics. 2024 Sep 18;16(9):1218. doi: 10.3390/pharmaceutics16091218.
5
Recent Review on Biological Barriers and Host-Material Interfaces in Precision Drug Delivery: Advancement in Biomaterial Engineering for Better Treatment Therapies.精准给药中的生物屏障与宿主-材料界面的最新综述：生物材料工程促进更好治疗方法的进展
Pharmaceutics. 2024 Aug 16;16(8):1076. doi: 10.3390/pharmaceutics16081076.
6
Recent Findings on Therapeutic Cancer Vaccines: An Updated Review.治疗性癌症疫苗的最新研究成果：最新综述
Biomolecules. 2024 Apr 21;14(4):503. doi: 10.3390/biom14040503.
7
Knowledge mapping of therapeutic cancer vaccine from 2013 to 2022: A bibliometric and visual analysis.2013 年至 2022 年治疗性癌症疫苗的知识图谱：文献计量学和可视化分析。
Hum Vaccin Immunother. 2023 Aug;19(2):2254262. doi: 10.1080/21645515.2023.2254262. Epub 2023 Sep 20.
8
Peptide-based vaccine for cancer therapies.基于肽的癌症治疗疫苗。
Front Immunol. 2023 Aug 16;14:1210044. doi: 10.3389/fimmu.2023.1210044. eCollection 2023.
9
Pharmacological impact of microRNAs in head and neck squamous cell carcinoma: Prevailing insights on molecular pathways, diagnosis, and nanomedicine treatment.微小RNA在头颈部鳞状细胞癌中的药理作用：关于分子途径、诊断及纳米医学治疗的当前见解
Front Pharmacol. 2023 May 3;14:1174330. doi: 10.3389/fphar.2023.1174330. eCollection 2023.
10
Aerosol pulmonary immune engineering.气溶胶肺部免疫工程。
Adv Drug Deliv Rev. 2023 Aug;199:114831. doi: 10.1016/j.addr.2023.114831. Epub 2023 Apr 24.
本文引用的文献
1
Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy.系统性 RNA 递送至树突状细胞利用抗病毒防御机制进行癌症免疫治疗。
Nature. 2016 Jun 16;534(7607):396-401. doi: 10.1038/nature18300. Epub 2016 Jun 1.
2
Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a randomised, double-blind, placebo-controlled, phase 3 trial.MAGE-A3 癌症免疫治疗作为辅助治疗在切除的 MAGE-A3 阳性非小细胞肺癌（MAGRIT）患者中的疗效：一项随机、双盲、安慰剂对照、3 期临床试验。
Lancet Oncol. 2016 Jun;17(6):822-835. doi: 10.1016/S1470-2045(16)00099-1. Epub 2016 Apr 27.
3
A non-randomized dose-escalation Phase I trial of a protein-based immunotherapeutic for the treatment of breast cancer patients with HER2-overexpressing tumors.一项基于蛋白质的免疫疗法用于治疗HER2过表达肿瘤的乳腺癌患者的非随机剂量递增I期试验。
Breast Cancer Res Treat. 2016 Apr;156(2):319-30. doi: 10.1007/s10549-016-3751-x. Epub 2016 Mar 18.
4
Cancer statistics, 2016.癌症统计数据，2016 年。
CA Cancer J Clin. 2016 Jan-Feb;66(1):7-30. doi: 10.3322/caac.21332. Epub 2016 Jan 7.
5
Nanoparticle surface charge impacts distribution, uptake and lymph node trafficking by pulmonary antigen-presenting cells.纳米颗粒表面电荷会影响肺部抗原呈递细胞的分布、摄取及淋巴结转运。
Nanomedicine. 2016 Apr;12(3):677-687. doi: 10.1016/j.nano.2015.11.002. Epub 2015 Dec 1.
6
A randomized pilot trial testing the safety and immunologic effects of a MAGE-A3 protein plus AS15 immunostimulant administered into muscle or into dermal/subcutaneous sites.一项随机试点试验，测试将MAGE - A3蛋白加AS15免疫刺激剂注入肌肉或真皮/皮下部位的安全性和免疫效果。
Cancer Immunol Immunother. 2016 Jan;65(1):25-36. doi: 10.1007/s00262-015-1770-9. Epub 2015 Nov 18.
7
Identification of QS-21 as an Inflammasome-activating Molecular Component of Saponin Adjuvants.鉴定QS-21为皂苷佐剂的一种炎性小体激活分子成分。
J Biol Chem. 2016 Jan 15;291(3):1123-36. doi: 10.1074/jbc.M115.683011. Epub 2015 Nov 10.
8
Optimization of Lipid Nanoparticle Formulations for mRNA Delivery in Vivo with Fractional Factorial and Definitive Screening Designs.优化用于体内 mRNA 传递的脂质纳米粒子配方：基于部分因子和确定筛设计。
Nano Lett. 2015 Nov 11;15(11):7300-6. doi: 10.1021/acs.nanolett.5b02497. Epub 2015 Oct 20.
9
Survivin-targeted immunotherapy drives robust polyfunctional T cell generation and differentiation in advanced ovarian cancer patients.靶向生存素的免疫疗法可促使晚期卵巢癌患者产生强大的多功能T细胞并使其分化。
Oncoimmunology. 2015 May 7;4(8):e1026529. doi: 10.1080/2162402X.2015.1026529. eCollection 2015 Aug.
10
Safety and Immunogenicity of MAGE-A3 Cancer Immunotherapeutic with or without Adjuvant Chemotherapy in Patients with Resected Stage IB to III MAGE-A3-Positive Non-Small-Cell Lung Cancer.MAGE-A3 癌症免疫治疗与或不与辅助化疗联合用于切除的 MAGE-A3 阳性非小细胞肺癌 IB 期至 III 期患者的安全性和免疫原性。
J Thorac Oncol. 2015 Oct;10(10):1458-67. doi: 10.1097/JTO.0000000000000653.
Zotero 插件